DrugPatentWatch Database Preview

Details for Patent: 10,231,964

« Back to Dashboard

Which drugs does patent 10,231,964 protect, and when does it expire?

Patent 10,231,964 protects CONTRAVE and is included in one NDA.

This patent has twenty-three patent family members in twenty countries.

Summary for Patent: 10,231,964

Title:	Compositions and methods for weight loss in at risk patient populations
Abstract:	The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
Inventor(s):	Klassen; Preston (La Jolla, CA), Taylor; Kristin (San Diego, CA)
Assignee:	Nalpropion Pharmaceuticals, Inc. (Morristown, NJ)
Application Number:	15/725,830
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,231,964

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes						FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

International Family Members for US Patent 10,231,964

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	098631
Australia	2014360492
Canada	2932127